Superstring Capital Management LP is an SEC-registered investment adviser based in New York, NY that reports managing 1 hedge fund on Form ADV. It reports $339.5 million in regulatory assets under management. Its private funds, of all types, hold $315.7 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +28.7% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +114.5% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $339.5 millionForm ADV Item 5.F
- Gross assets of private funds
- $315.7 millionAll private fund types, Form ADV
- Hedge funds managed
- 12 private funds in total
- Employees
- 5Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 305743
- Latest Form ADV
- 03/30/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +26.7% | +14.8% |
| Q1 2026 | +1.6% | -4.6% |
| Q4 2025 | +43.8% | +2.4% |
| Q3 2025 | +38.4% | +7.8% |
| Q2 2025 | +12.9% | +10.4% |
| Q1 2025 | -16.1% | -4.5% |
| Q4 2024 | -17.9% | +2.1% |
| Q3 2024 | +7.7% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
All 35 share positions ($199,517,915) reported by Superstring Capital Management LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Cogent Biosciences Inc9.59%
- Axsome Therapeutics Inc.9.47%
- Trevi Therapeutics Inc7.07%
- Genmab A/s6.54%
- Climb Bio Inc5.28%
- Zai Lab LTD4.79%
- Adlai Nortye LTD4.72%
- Revolution Medicines Inc4.30%
- Celldex Therapeutics Inc New3.94%
- Immunovant Inc3.76%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Cogent Biosciences Inc | $19,129,004 | 9.59% | 597,408 | +74.03% |
| Axsome Therapeutics Inc. | $18,897,209 | 9.47% | 102,485 | +90.08% |
| Trevi Therapeutics Inc | $14,103,653 | 7.07% | 984,892 | +87.88% |
| Genmab A/s | $13,044,992 | 6.54% | 365,662 | -15.08% |
| Climb Bio Inc | $10,532,110 | 5.28% | 918,231 | +76.22% |
| Zai Lab LTD | $9,552,754 | 4.79% | 362,671 | +132.76% |
| Adlai Nortye LTD | $9,414,688 | 4.72% | 588,418 | +6.50% |
| Revolution Medicines Inc | $8,576,584 | 4.30% | 41,784 | -18.16% |
| Celldex Therapeutics Inc New | $7,859,198 | 3.94% | 242,493 | -15.68% |
| Immunovant Inc | $7,503,247 | 3.76% | 222,121 | +6.60% |
| Urogen Pharma LTD | $7,491,847 | 3.75% | 184,392 | -3.62% |
| United Therapeutics Corp Del | $7,218,517 | 3.62% | 13,321 | +85.74% |
| Legend Biotech Corp | $7,107,871 | 3.56% | 357,359 | New |
| Definium Therapeutics Inc | $6,719,912 | 3.37% | 176,561 | -6.23% |
| Roivant Sciences LTD | $6,540,252 | 3.28% | 178,842 | +597.97% |
| Vir Biotechnology Inc | $6,469,821 | 3.24% | 578,696 | -32.21% |
| Ionis Pharmaceuticals Inc | $5,908,936 | 2.96% | 132,339 | New |
| Savara Inc | $5,251,936 | 2.63% | 1,017,817 | +4.13% |
| Sagimet Biosciences Inc | $4,179,299 | 2.09% | 423,006 | New |
| Abivax SA | $2,972,580 | 1.49% | 30,020 | New |
| Ginkgo Bioworks Holdings Inc | $2,855,355 | 1.43% | 222,553 | New |
| Spyre Therapeutics Inc | $2,672,859 | 1.34% | 30,022 | New |
| Bright Minds Biosciences Inc | $2,393,602 | 1.20% | 48,045 | +57.75% |
| Kiniksa Pharmaceuticals Intl | $2,363,943 | 1.18% | 31,684 | +67.93% |
| Taysha Gene Therapies Inc | $2,013,127 | 1.01% | 413,373 | New |
| Latigo Biotherapeutics Inc | $1,472,573 | 0.74% | 88,178 | New |
| Oruka Therapeutics Inc | $1,286,497 | 0.64% | 15,446 | New |
| Maplight Therapeutics Inc | $1,205,518 | 0.60% | 118,304 | -5.68% |
| Madrigal Pharmaceuticals Inc | $1,057,812 | 0.53% | 2,099 | New |
| Cabaletta Bio Inc | $993,431 | 0.50% | 517,412 | -59.53% |
| Xenon Pharmaceuticals Inc | $985,386 | 0.49% | 26,496 | New |
| Tonix Pharmaceuticals Hldg C | $727,461 | 0.36% | 74,688 | +17.35% |
| Boundless Bio Inc | $517,667 | 0.26% | 206,242 | +272.57% |
| Grail Inc | $453,709 | 0.23% | 3,238 | New |
| Biomea Fusion Inc | $44,565 | 0.02% | 225,872 | -9.65% |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 12 new positions, 9 sold out, 14 increased, 9 reduced and 0 unchanged.
Number of positions (a count, not dollars)
- New positions12
- Increased14
- Unchanged0
- Reduced9
- Sold out9
New positions
| Stock | Value | Shares |
|---|---|---|
| Legend Biotech Corp | $7,107,871 | 357,359 |
| Ionis Pharmaceuticals Inc | $5,908,936 | 132,339 |
| Sagimet Biosciences Inc | $4,179,299 | 423,006 |
| Abivax SA | $2,972,580 | 30,020 |
| Ginkgo Bioworks Holdings Inc | $2,855,355 | 222,553 |
| Spyre Therapeutics Inc | $2,672,859 | 30,022 |
| Taysha Gene Therapies Inc | $2,013,127 | 413,373 |
| Latigo Biotherapeutics Inc | $1,472,573 | 88,178 |
| Oruka Therapeutics Inc | $1,286,497 | 15,446 |
| Madrigal Pharmaceuticals Inc | $1,057,812 | 2,099 |
| Xenon Pharmaceuticals Inc | $985,386 | 26,496 |
| Grail Inc | $453,709 | 3,238 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Oric Pharmaceuticals Inc | $4,397,814 | 406,077 |
| Vaxcyte Inc | $3,882,677 | 66,793 |
| Beone Medicines LTD | $3,497,437 | 12,273 |
| Sionna Therapeutics Inc | $2,778,232 | 63,156 |
| Aclaris Therapeutics Inc | $1,363,101 | 257,675 |
| Cybin Inc | $1,351,243 | 204,424 |
| Protara Therapeutics Inc | $463,966 | 121,457 |
| Faeth Therapeutics Inc | $354,375 | 14,175 |
| Vyne Therapeutics Inc | $39,868 | 61,269 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Axsome Therapeutics Inc. | +48,569 | +90.08% | $18,897,209 | 102,485 |
| Cogent Biosciences Inc | +254,124 | +74.03% | $19,129,004 | 597,408 |
| Trevi Therapeutics Inc | +460,668 | +87.88% | $14,103,653 | 984,892 |
| Roivant Sciences LTD | +153,219 | +597.97% | $6,540,252 | 178,842 |
| Zai Lab LTD | +206,858 | +132.76% | $9,552,754 | 362,671 |
| Climb Bio Inc | +397,149 | +76.22% | $10,532,110 | 918,231 |
| United Therapeutics Corp Del | +6,149 | +85.74% | $7,218,517 | 13,321 |
| Kiniksa Pharmaceuticals Intl | +12,817 | +67.93% | $2,363,943 | 31,684 |
| Bright Minds Biosciences Inc | +17,589 | +57.75% | $2,393,602 | 48,045 |
| Adlai Nortye LTD | +35,917 | +6.50% | $9,414,688 | 588,418 |
| Immunovant Inc | +13,753 | +6.60% | $7,503,247 | 222,121 |
| Boundless Bio Inc | +150,886 | +272.57% | $517,667 | 206,242 |
| Savara Inc | +40,357 | +4.13% | $5,251,936 | 1,017,817 |
| Tonix Pharmaceuticals Hldg C | +11,040 | +17.35% | $727,461 | 74,688 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Vir Biotechnology Inc | -274,989 | -32.21% | $6,469,821 | 578,696 |
| Genmab A/s | -64,938 | -15.08% | $13,044,992 | 365,662 |
| Revolution Medicines Inc | -9,269 | -18.16% | $8,576,584 | 41,784 |
| Cabaletta Bio Inc | -761,240 | -59.53% | $993,431 | 517,412 |
| Celldex Therapeutics Inc New | -45,090 | -15.68% | $7,859,198 | 242,493 |
| Definium Therapeutics Inc | -11,721 | -6.23% | $6,719,912 | 176,561 |
| Urogen Pharma LTD | -6,921 | -3.62% | $7,491,847 | 184,392 |
| Maplight Therapeutics Inc | -7,128 | -5.68% | $1,205,518 | 118,304 |
| Biomea Fusion Inc | -24,128 | -9.65% | $44,565 | 225,872 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Private funds reported on Form ADV (2)
As reported in the adviser's Form ADV filed Mar 28, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures